Enhanced Antitumor Effect of Oncolytic Virotherapy Combined with mRNA-Encoded Immunoadjuvants in Colorectal Carcinoma (CT26) Tumor Model
Authors:
- Anastasia RyapolovaARAnastasia Ryapolova
- Daniil ShevyrevDaniil Shevyrev
- Angela TsvetkovaATAngela Tsvetkova
- Olesya SokolovaOSOlesya Sokolova
- Olga VasilevaOVOlga Vasileva
- Vladimir AndriianovVAVladimir Andriianov
- Bogdan KrapivinBKBogdan Krapivin
- Alena KozlovaAKAlena Kozlova
- Kristina VoronaKVKristina Vorona
- Sofia KondratievaSKSofia Kondratieva
- Roman A. IvanovRIRoman A. Ivanov
- Alexander KarabelskyAKAlexander Karabelsky
Open Access
- 22 December 2025
- journal article
- research article
- Published by MDPI AG in Applied Biosciences
- Vol. 5 (1) , 1
Abstract
The search for effective anti-cancer therapies is one of the most significant goals of modern medicine. The combination of oncolytic viruses (OV) and mRNA immunoadjuvants can significantly improve the outcome or even substitute traditional immunotherapy. In addition to the direct OV-mediated cytotoxic elimination of tumor cells, both OV and mRNA immunoadjuvants can significantly alter the immunosuppressive tumor microenvironment (TME) supporting cancer cells and unleash the immune response against the malignant cells. The present study is aimed at assessing the therapeutic effects of recombinant vesicular stomatitis virus (rVSV) and lipid nanoparticles (LNP) delivering mRNA coding for murine interleukin-12 (mIL12) and granulocyte-macrophage colony-stimulating factor (mGMCSF) (mRNA-LNP) in colorectal carcinoma CT26-induced tumors both as independent therapies and in combination with each other. The results of the in vivo experiment on BALB/c mice demonstrated that rVSV monotherapy did not have a significant effect, with the tumor growth inhibition index (TGII) ranging from 13.7 to 29.8% on days 6–10 after the therapy start. While monotherapy with mRNA-LNP was more effective (TGII of 48.6–53.7%), it was the therapy combining the two approaches (rVSV and mRNA-LNP) that resulted in the highest TGII of 66.7% on day 10. While these results can be further improved by optimizing the experimental design, they show the great potential of combination immunotherapy for the treatment of oncological diseases.Keywords
Funding Information
- “Sirius” Federal Territory “Scientific and technological development of the “Sirius” Federal Territory” (18-03)
This publication has 61 references indexed in Scilit:
- Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor-resistant tumors resulting in complete responsesCancer Immunology, Immunotherapy, 2025
- An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant GliomasCurrent Treatment Options in Oncology, 2024
- Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancerMolecular Therapy Oncology, 2024
- Modeling of the human interleukin 12:receptor complex allows to engineer attenuated cytokine variantsMolecular Immunology, 2023
- Intratumoral injection of IL-12-encoding mRNA targeted to CSF1R and PD-L1 exerts potent anti-tumor effects without substantial systemic exposureMolecular Therapy Nucleic Acids, 2023
- Born to kill: arming oncolytic virus VSV-TNFSF14/light to treat metastatic pancreatic cancerHPB, 2023
- Novel strategies exploiting interleukin-12 in cancer immunotherapyPharmacology & Therapeutics, 2022
- Steps in metastasis: an updated reviewMedical Oncology, 2021
- On the Calculation of TCID50 for Quantitation of Virus InfectivityVirologica Sinica, 2020
- The advent of oncolytic virotherapy in oncology: The Rigvir® storyEuropean Journal of Pharmacology, 2018